BEVERLY HILLS, Calif., June 30 /PRNewswire-FirstCall/ — OXIS
INTERNATIONAL, INC. (OTC Bulletin Board: OXIS, Paris: OXI), is
extremely pleased to announce that it has assumed control and
future exploitation rights to International Patent PCT Application
PCY/US2008/059831. The invention centers on the use of
L-Ergothioneine (“ERGO”) as a primary preservative for cells and
tissue in culture. Such preservatives are essential for keeping
cells in their “normal” state for later use or study and for
transporting cells without damage. Today, freezing is the
primary method for cell preservation. But freezing often
compromises the recovery and/or normal function of the cells.
One of the many practical applications of this improved
method of preservation is for artificial insemination, where the
ability to more easily preserve, transport and use sperm cells
without alteration offers many advantages. This offers significant
value if the sperm can be preserved and kept viable for extended
periods time. ERGO has been shown to be highly effective as a
cellular preservative, not only for cells and tissue but organs as
well. In that regard, ERGO may well offer a further future
opportunity as a preservative for transplant organs. OXIS and its
active scientific board will continue to research and deliver
important and practical new applications for ERGO that represent
significant market opportunities for the Company. “This patent
filing reinforces the efficacy and market opportunity approach OXIS
is currently taking with this breakthrough antioxidant,” added
Tony Cataldo, CEO.
About OXIS International, Inc.
OXIS International, Inc. develops technologies and products to
research, diagnose, treat and prevent diseases of oxidative
stress/inflammation associated with damage fro
‘/>”/>